Last updated on March 2020

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Brief description of study

The purpose of this study is to determine whether BMS-986258 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors

Clinical Study Identifier: NCT03446040

Find a site near you

Start Over

Local Institution

Heidelberg, Australia
  Connect »